Abstract

K. Satyavathi¹*, Naga Jahnavi Vemu² and Saalim Mohammed²

According to the present statistics in an year around 5% of women aged 30-49 years visit their general practitioners with menorrhagia. Every year in the United Kingdom around 45,000 hysterectomies and a further 10,000 endometrial ablations are performed for menorrhagia. Of the many antifibrinolytic drugs tranexamic acid is majorly used to treat excessive bleeding. It is of proven value in clearing the field of surgery and reducing pre and postoperative blood loss. Unlike other antifibrinolytic drugs, the side effects of tranexamic acid are uncommon. Prolonged treatment may heighten the risk of an increased thrombotic tendency, such as deep vein thrombosis, yet it is used in obstetrics, dentistry, cardiac surgery, orthopedic surgery, hemophilia, angioedema. It is a structural analog of lysine. It is 6-10 times more effective than aminocaproic acid. Present article on tranexamic acid gives a review on the pharmacological and analytical profile, synthesis, development, and utility of this drug in wide variety of fields.

Antifibrinolytic agent; Tranexamic acid; bleeding

[ View HTML Full Text]